Molecular Prognostication of Non-Small Cell Lung Cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 25, Issue 1, 2013, Pages 4-7

  Tsao, Ming Sound ^a,b   Jablons, David M ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FORMALDEHYDE; K RAS PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA; NAVELBINE; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EXCISION REPAIR; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879538777     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2013.01.007     Document Type: Article

References (28)

1. Shepherd F.A., Tsao M.S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006, 24:1219-1220.
2. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
3. Zhu C.Q., Shih W., Ling C.H., et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006, 59:790-800.
4. Sève P., Lai R., Ding K., et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 2007, 13:994-999.
5. Reiman T., Lai R., Veillard A.S., et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. Ann Oncol 2012, 23:86-93.
6. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
7. Mascaux C., Iannino N., Martin B., et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2005, 92:131-139.
8. Tsao M.S., Hainaut P., Bourredjem A., et al. LACE-BIO pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21:viii63. Abstract 1506.
9. Tsao M.S., Aviel-Ronen S., Ding K., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240-5247.
10. Loriot Y., Mordant P., Deutsch E., et al. Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nat Rev Clin Oncol 2009, 6:528-534.
11. D'Amico T.A., Massey M., Herndon J.E., et al. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999, 117:736-743.
12. Kwiatkowski D.J., Harpole D.H., Godleski J., et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 1998, 16:2468-2477.
13. Zhu C.Q., Pintilie M., John T., et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer 2009, 10:331-340.
14. Boutros P.C., Lau S.K., Pintilie M., et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 2009, 106:2824-2828.
15. Shedden K., Taylor J.M., Enkemann S.A., et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008, 14:822-827.
16. Zhu C.Q., Ding K., Strumpf D., et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010, 28:4417-4424.
17. Kratz J.R., He J., Van Den Eeden S.K., et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies. Lancet 2012, 379:823-832.
18. Kratz J.R., Van den Eeden S.K., He J., et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 2012, 308:1629-1631.
19. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
20. Riely G.J., Politi K.A., Miller V.A., et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12:7232-7241.
21. Sasaki H., Shimizu S., Endo K., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118:180-184.
22. Kosaka T., Yatabe Y., Onozato R., et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009, 4:22-29.
23. Kim Y.T., Seong Y.W., Jung Y.J., et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013, 8:171-178.
24. Bogner P.N., Patnaik S.K., Pitoniak R., et al. Lung cancer xenografting alters microRNA profile but not immunophenotype. Biochem Biophys Res Commun 2009, 386:305-310.
25. Raponi M., Dossey L., Jatkoe T., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69:5776-5783.
26. Hu Z., Chen X., Zhao Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726.
27. Tan X., Qin W., Zhang L., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011, 17:6802-6811.
28. Duncavage E., Goodgame B., Sezhiyan A., et al. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 2010, 5:1755-1763.